UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy

Annals of oncology, 2021-12, Vol.32 (12), p.1637-1642

2021

Volltextzugriff (PDF)

Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy

Annals of oncology, 2016-08, Vol.27 (8), p.1482-1492

2016

Volltextzugriff (PDF)

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

Annals of oncology, 2016-04, Vol.27 (4), p.559-574

2016

Volltextzugriff (PDF)

Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer

Annals of oncology, 2018-01, Vol.29 (suppl_1), p.i28-i37

2018

Volltextzugriff (PDF)

Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor

Annals of oncology, 2019-08, Vol.30 (8), p.1401-1403

2019

Volltextzugriff (PDF)

Prioritizing targets for precision cancer medicine

Annals of oncology, 2014-12, Vol.25 (12), p.2295-2303

2014

Volltextzugriff (PDF)

Epigenetic modifiers as new immunomodulatory therapies in solid tumours

Annals of oncology, 2018-04, Vol.29 (4), p.812-824

2018

Volltextzugriff (PDF)

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma

Annals of oncology, 2018-03, Vol.29 (3), p.700-706

2018

Volltextzugriff (PDF)

Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer

Annals of oncology, 2013-01, Vol.24 (1), p.20-30

2013

Volltextzugriff (PDF)

First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer

Annals of oncology, 2018-09, Vol.29 (9), p.1911-1917

2018

Volltextzugriff (PDF)

Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors

Annals of oncology, 2014-11, Vol.25 (11), p.2244-2251

2014

Volltextzugriff (PDF)

The art of innovation: clinical development of trastuzumab deruxtecan and redefining how antibody-drug conjugates target HER2-positive cancers

Annals of oncology, 2020-03, Vol.31 (3), p.430-434

2020

Volltextzugriff (PDF)

Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria

European journal of cancer (1990), 2018-01, Vol.88, p.38-47

2018

Volltextzugriff (PDF)

Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies

Annals of oncology, 2016-02, Vol.27 (2), p.214-224

2016

Volltextzugriff (PDF)

Tumour stem cell-targeted treatment: elimination or differentiation

Annals of oncology, 2006-11, Vol.17 (11), p.1620-1624

2006

Volltextzugriff (PDF)

Small cell lung cancer: a slightly less orphan disease after immunotherapy

Annals of oncology, 2021-06, Vol.32 (6), p.698-709

2021

Volltextzugriff (PDF)

Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer

Annals of oncology, 2021-12, Vol.32 (12), p.1597-1607

2021

Volltextzugriff (PDF)

Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism

Annals of oncology, 2017-02, Vol.28 (2), p.254-269

2017

Volltextzugriff (PDF)

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

The New England journal of medicine, 2018-01, Vol.378 (2), p.113-125

2018

Volltextzugriff (PDF)

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

European journal of cancer (1990), 2016-02, Vol.54, p.139-148

2016

Volltextzugriff (PDF)

A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups

Annals of oncology, 2017-07, Vol.28 (7), p.1523-1531

2017

Volltextzugriff (PDF)

Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors

Annals of oncology, 2009-10, Vol.20 (10), p.1674-1681

2009

Volltextzugriff (PDF)

Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer

Annals of oncology, 2020-03, Vol.31 (3), p.377-386

2020

Volltextzugriff (PDF)

High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer

Annals of oncology, 2015-07, Vol.26 (7), p.1408-1415

2015

Volltextzugriff (PDF)

Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors

Annals of oncology, 2022-10, Vol.33 (10), p.1041-1051

2022

Volltextzugriff (PDF)

1 – 25 von 6.337

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(5.387)
Mit Volltextzugriff
(4.996)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

5 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(3.016)
Life Sciences & Biomedicine
(1.899)
Humans
(1.705)
Female
(897)
Male
(862)
Physical Sciences
(795)
Technology
(667)
Biological And Medical Sciences
(627)
Middle Aged
(565)
Adult
(557)
Aged
(449)
Medical Sciences
(446)
Animals
(441)
Oncology
(378)
Exact Sciences And Technology
(371)
Chemistry
(347)
Physics
(318)
Engineering
(315)
Fundamental And Applied Biological Sciences. Psychology
(214)
Adolescent
(200)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

IngentaConnect Journals
(2.763)
EZB Electronic Journals Library
(2.584)
MEDLINE
(2.092)
Access via ScienceDirect (Elsevier)
(1.900)
Journals@Ovid Full Text
(1.482)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(865)
NUS Single-Journal Subscriptions
(826)
IngentaConnect Journals
(713)
Wiley Online Library Journals
(543)
Wiley Online Library Full Collection 2018
(384)
Springer journals
(352)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(218)
IEEE Electronic Library Online
(185)
Oxford journals
(178)
Nature Journals
(136)
HEAL-Link subscriptions: Springer Book Series
(126)
Taylor & Francis Journals Complete
(121)
Taylor & Francis
(114)
Access via Taylor & Francis
(113)
eBooks on EBSCOhost
(105)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy

Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer

Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor

Prioritizing targets for precision cancer medicine

Epigenetic modifiers as new immunomodulatory therapies in solid tumours

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma

Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer

First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer

Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors

The art of innovation: clinical development of trastuzumab deruxtecan and redefining how antibody-drug conjugates target HER2-positive cancers

Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria

Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies

Tumour stem cell-targeted treatment: elimination or differentiation

Small cell lung cancer: a slightly less orphan disease after immunotherapy

Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer

Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups

Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors

Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer

High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer

Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors

Suchergebnisse filtern